Oday Hamid
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Pathology and Forensic Medicine top 10%
- Cancer Mechanisms and Therapy
Papers in
- Oncology 23
- Cancer Immunotherapy and Biomarkers 9
- Lung Cancer Research Studies 4
- CAR-T cell therapy research 3
-
- Lymphoma Diagnosis and Treatment 7
- Co-authors
- Mary Varterasian (3 shared papers)Eric Kaldjian (4 shared papers)David Mitchell (1 shared paper)John J. Rinehart (1 shared paper)Judith S. Sebolt–Leopold (1 shared paper)Patricia LoRusso (1 shared paper)David Waterhouse (1 shared paper)Mark B. Meyer (1 shared paper)
- Journals
- Journal of Clinical Oncology (16 papers)Annals of Oncology (4 papers)European Journal of Cancer (4 papers)Blood (2 papers)Cancer Research (2 papers)
- Partner nations
- United StatesFranceSouth Korea
In The Last Decade
Oday Hamid
41 papers receiving 1.2k citations
Oday Hamid's Hit Papers
Peers
Comparison fields: 5 of 68
- Oncology 629
- Pathology and Forensic Medicine 184
- Molecular Biology 642
- Immunology 165
- Genetics 80
Countries citing papers authored by Oday Hamid
This map shows the geographic impact of Oday Hamid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oday Hamid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oday Hamid more than expected).
Fields of papers citing papers by Oday Hamid
This network shows the impact of papers produced by Oday Hamid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oday Hamid. The network helps show where Oday Hamid may publish in the future.
Co-authors
The 25 scholars most cited alongside Oday Hamid, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer Hit paper breakdown → | 2004 | 524 |
| 2 | 2003 | 113 | |
| 3 | 2005 | 91 | |
| 4 | 2017 | 70 | |
| 5 | 2017 | 58 | |
| 6 | 2016 | 56 | |
| 7 | 2018 | 42 | |
| 8 | 2020 | 39 | |
| 9 | 2011 | 30 | |
| 10 | 2013 | 24 | |
| 11 | 2004 | 22 | |
| 12 | 2020 | 19 | |
| 13 | 2011 | 19 | |
| 14 | 2015 | 14 | |
| 15 | 2014 | 14 | |
| 16 | 2004 | 14 | |
| 17 | 2023 | 13 | |
| 18 | 2021 | 12 | |
| 19 | 2004 | 9 | |
| 20 | 2011 | 8 |
About Oday Hamid
Oday Hamid is a scholar working on Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Molecular Biology and Surgery, having authored 41 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Lymphoma Diagnosis and Treatment (7 papers), Bladder and Urothelial Cancer Treatments (5 papers), Immunotherapy and Immune Responses (5 papers), Lung Cancer Research Studies (4 papers), Chronic Lymphocytic Leukemia Research (4 papers), Lung Cancer Treatments and Mutations (4 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Oncology (629 citations), Pathology and Forensic Medicine (184 citations), Molecular Biology (642 citations), Immunology (165 citations) and Genetics (80 citations). Oday Hamid has collaborated with scholars based in United States, France and South Korea. Frequent co-authors include Mary Varterasian, Eric Kaldjian, David Mitchell, John J. Rinehart, Judith S. Sebolt–Leopold, Patricia LoRusso, David Waterhouse, Mark B. Meyer, J. Randolph Hecht and Román Herrera. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Blood and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.